Matches in Wikidata for { <http://www.wikidata.org/entity/Q66405307> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- Q66405307 description "clinical trial" @default.
- Q66405307 description "ensayu clínicu" @default.
- Q66405307 description "klinisch onderzoek" @default.
- Q66405307 description "клінічне випробування" @default.
- Q66405307 name "Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab" @default.
- Q66405307 name "Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab" @default.
- Q66405307 type Item @default.
- Q66405307 label "Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab" @default.
- Q66405307 label "Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab" @default.
- Q66405307 prefLabel "Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab" @default.
- Q66405307 prefLabel "Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab" @default.
- Q66405307 P1050 Q66405307-4D7940A4-988D-4307-B1E3-38C006D2CAF8 @default.
- Q66405307 P1132 Q66405307-5FFD6D1F-E97C-4FD8-9E8D-BD19799DF40E @default.
- Q66405307 P1476 Q66405307-72A48FC4-2830-481E-B9A1-1102AEA4E9EF @default.
- Q66405307 P17 Q66405307-2E178760-6A0B-44D5-86CE-1F0AE7AA9557 @default.
- Q66405307 P17 Q66405307-30DC85CC-F505-4C41-B105-F10E459F6DB3 @default.
- Q66405307 P17 Q66405307-312AC0DA-04BC-433A-A95C-2EB7CB830D57 @default.
- Q66405307 P17 Q66405307-312C9927-F85D-4460-902E-081FC4D4420F @default.
- Q66405307 P17 Q66405307-3BC1E584-3FC0-456D-997B-F124C4AB5DBD @default.
- Q66405307 P17 Q66405307-3FA24570-15CC-4542-B348-0138973F3EED @default.
- Q66405307 P17 Q66405307-485DFBFB-F46A-4E57-AD73-65F3B2145EE5 @default.
- Q66405307 P17 Q66405307-48C69CDD-1596-40DD-A9C7-9FADFBD90BBD @default.
- Q66405307 P17 Q66405307-4D170B67-7F4E-49A7-92CD-38AC071B6C5D @default.
- Q66405307 P17 Q66405307-61A6BFB6-0B2A-49BB-A44A-72E649FAFAA4 @default.
- Q66405307 P17 Q66405307-70B570E5-A59D-4E66-B772-A5ACB316506A @default.
- Q66405307 P17 Q66405307-8D18BD7B-D8CF-4BBE-B374-562CFB69C2A8 @default.
- Q66405307 P17 Q66405307-A5E6F865-B505-46C4-BFA2-AC88327F2E8B @default.
- Q66405307 P17 Q66405307-AFA83DF3-763A-4131-9C36-D979349123FB @default.
- Q66405307 P17 Q66405307-CFEE9814-90DD-4460-90C9-B529B065B9E2 @default.
- Q66405307 P17 Q66405307-ECE2F440-9CCD-4777-BCAA-E3CCDD0DAEC0 @default.
- Q66405307 P17 Q66405307-F3BA7D2E-93EE-4D8C-A877-98D98729470D @default.
- Q66405307 P17 Q66405307-FD7F9072-BD62-4481-829A-469ABFF47D91 @default.
- Q66405307 P1813 Q66405307-40F702B6-2AC0-4D96-A8D2-C6C0F661B582 @default.
- Q66405307 P2899 Q66405307-AFED3081-1D1E-4276-8FEE-AD7439C4EE0B @default.
- Q66405307 P3098 Q66405307-25095EB2-0C46-48BE-B45E-71BD921929EC @default.
- Q66405307 P31 Q66405307-0DADD223-B91D-41F1-A066-85BBA7B5A4F6 @default.
- Q66405307 P4844 Q66405307-E357257C-1F65-4DE3-A1F0-7B4A859C5135 @default.
- Q66405307 P580 Q66405307-E8387273-15EA-4291-A8B3-651B0E1E76C2 @default.
- Q66405307 P582 Q66405307-A48FBD7D-D18C-4318-8A03-A6958C2DC4A7 @default.
- Q66405307 P6099 Q66405307-258FE04E-D49F-4BB0-82EA-F7BDEBE9838F @default.
- Q66405307 P8363 Q66405307-ECC9B8CA-7F5C-478F-8FB9-F6F6A1769279 @default.
- Q66405307 P1050 Q208414 @default.
- Q66405307 P1132 "+256" @default.
- Q66405307 P1476 "A Randomized, Double-Blind Study Evaluating the Efficacy, Safety and Immunogenicity of ABP 798 Compared With Rituximab in Subjects With CD20 Positive B-Cell Non-Hodgkin Lymphoma (NHL)" @default.
- Q66405307 P17 Q142 @default.
- Q66405307 P17 Q16 @default.
- Q66405307 P17 Q17 @default.
- Q66405307 P17 Q183 @default.
- Q66405307 P17 Q212 @default.
- Q66405307 P17 Q218 @default.
- Q66405307 P17 Q219 @default.
- Q66405307 P17 Q230 @default.
- Q66405307 P17 Q29 @default.
- Q66405307 P17 Q30 @default.
- Q66405307 P17 Q36 @default.
- Q66405307 P17 Q38 @default.
- Q66405307 P17 Q408 @default.
- Q66405307 P17 Q41 @default.
- Q66405307 P17 Q668 @default.
- Q66405307 P17 Q739 @default.
- Q66405307 P17 Q801 @default.
- Q66405307 P17 Q96 @default.
- Q66405307 P1813 "JASMINE" @default.
- Q66405307 P2899 "+18" @default.
- Q66405307 P3098 "NCT02747043" @default.
- Q66405307 P31 Q30612 @default.
- Q66405307 P4844 Q412323 @default.
- Q66405307 P580 "2016-05-25T00:00:00Z" @default.
- Q66405307 P582 "2019-06-28T00:00:00Z" @default.
- Q66405307 P6099 Q42824827 @default.
- Q66405307 P8363 Q78089383 @default.